Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Qlife Holding AB's 5-Year RORE % for the quarter that ended in Mar. 2026 was -37.52%.
The industry rank for Qlife Holding AB's 5-Year RORE % or its related term are showing as below:
OSTO:QLIFE's 5-Year RORE % is ranked worse than 80.77% of 702
companies
in the Medical Devices & Instruments industry
Industry Median: -5.03
vs OSTO:QLIFE: -37.52
Qlife Holding AB (OSTO:QLIFE) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Qlife Holding AB 5-Year RORE % Related Terms
Qlife Holding AB 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Qlife Holding AB's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:QLIFE vs ABT, SYK, MDT: 5-Year RORE % Comparison
For the Medical Devices subindustry, Qlife Holding AB's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qlife Holding AB 5-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Qlife Holding AB's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Qlife Holding AB's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
Qlife Holding AB (OSTO:QLIFE) has a 5-Year RORE % of -37.52 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Qlife Holding AB and its competitors. According to the industry distribution chart, Qlife Holding AB ranks #567 out of 702 companies in the Medical Devices & Instruments industry, placing it in the top 80.8%.
Is Qlife Holding AB's 5-Year RORE % too high?
Qlife Holding AB's current 5-Year RORE % is -37.52. Based on the distribution chart, Qlife Holding AB ranks #567 out of 702 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Qlife Holding AB has a GF Score™ of 18/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qlife Holding AB's 5-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Qlife Holding AB ranks #567 out of 702 companies for 5-Year RORE %. This places Qlife Holding AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Medical Devices & Instruments company?
A good 5-Year RORE % depends on the Medical Devices & Instruments industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Qlife Holding AB and its competitors. Qlife Holding AB's current 5-Year RORE % is -37.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qlife Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Qlife Holding AB (OSTO:QLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.75, compared to a current price of kr1.81 — trading 141.1% above its estimated fair value. The current 5-Year RORE % is -37.52. Qlife Holding AB's overall GF Score™ is 18/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Qlife Holding AB (OSTO:QLIFE), the current 5-Year RORE % is -37.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qlife Holding AB (OSTO:QLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Qlife Holding AB stock appears to be overvalued.
The current stock price of kr1.81 is trading 141.1% above its estimated GF Value™ of kr0.75.
GuruFocus considers Qlife Holding AB to be Significantly Overvalued.
Key valuation signals for OSTO:QLIFE:
5-Year RORE %: -37.52
GF Value™: kr0.75 vs. price of kr1.81 (141.1% above fair value)
No single metric tells the full story. See the OSTO:QLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
18GF Score
Get the complete analysis for OSTO:QLIFE
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:QLIFE has been successfully added to your 
